quirements or warfarin sensitivity in Brazilian populations (Fohner, Brackman, Giacomini, Altman, & Klein, 2017) . Shi et al. researched the genetic polymorphism of VIP variation in the pharmacogenomic of the Himalayan Deng people in southeast Tibet . Li et al. investigated the genetic polymorphism of very important pharmacogenomic variants in the Zhuang ethnic group of Southwestern China (Li et al., 2018) . However, no report has addressed studies of pharmacogenomics information regarding the Bai nationality. Here, we are the first to propose a systematic research on the genetic polymorphism of VIP variants in the Bai ethnic group, which is of great significance for understanding the Bai population and further helping to diagnose, prevent and treat specific diseases.
In this study, we randomly selected and genotyped 81 VIP variants from the PharmGKB database in 100 Dali Bai Autonomous Prefecture from Yunnan province, aimed to identify the allele frequencies of VIP variants in the Bai nationality and to determine the difference in allele frequencies between the Bai nationality and 11 populations from the HapMap data set. The results could not only expand our understanding of ethnic diversity and pharmacogenomics, but also provide a solid theoretical basis for safer administration of drugs and better individualized treatments among the Bai population.
| METHODS

| Ethics statement
All volunteers were informed about the procedures and purpose of the study, both orally and in writing. They also agreed to provide blood samples and signed informed consent forms. The clinical protocol was approved by the Ethics Committee of Yunnan First People's Hospital and was performed in accordance with the Declaration of Helsinki.
| Study participants
According to detailed recruitment and exclusion criteria, we recruited a random sample of 200 healthy, unrelated white people (100 men and 100 women) from Dali Bai Autonomous Prefecture in China's Yunnan province between July and October 2017. The incorporation criteria for all participants were as follows: (a) All individuals had exclusive Bai ancestry for at least the past three generations; (b) There was no genetic relationship among all participants; (c) All subjects were confirmed to be in good health through a routine medical history and physical examination and had no hereditary disease.
| VIP loci selection and genotyping
We searched the PharmGKB database (https ://www.pharm gkb.org/) and 81 random VIP variants of 40 genes were ultimately selected for our study according to available data on frequency, functionality, and linkage based on published research. The minor allele frequency of these SNPs sites in Chinese Han population was >0.05, which increase the statistical efficacy. According to the manufacturer's protocols, the genomic DNA was extracted from peripheral blood (5 ml) using a GoldMag-Mini Whole Blood Genomic DNA Purification Kit (GoldMag Co. Ltd., Xi'an, China). Then we measured the DNA concentration and purity with the NanoDrop spectrophotometer 2000 C (Thermo Scientific, Waltham, Massachusetts, USA). We designed polymerase chain reaction extended primers for these SNPS using the MassARRAY Assay Design 3.0 software. Agena MassARRAY RS1000 instrument (Shanghai, China) system was used for SNP genotyping analysis according to the standard scheme recommended by the manufacturer (Gabriel, Ziaugra, & Tabbaa, 2009) . SNPs genotyping data were managed and analyzed by Agena Typer 4.0 software.
| HapMap genotype data
The genotype data of the 11 populations were downloaded from the International HapMap Project web site (HapMap release127) at http://hapmap.ncbi.nlm.nih.gov.
The 11 
| Statistical analysis
We performed data processing and statistical analysis using Microsoft Excel (Redmond, WA, USA) and SPSS 17.0 statistical software package (SPSS, Chicago, IL, USA), including Hardy-Weinberg equilibrium (HWE) analysis and χ 2 test. Accurate testing was used to determine whether the genotype frequency of each VIP variant in the Bai populations deviated from the HWE balance. The genotype frequencies of the Bai and 11 HapMap populations were calculated and compared using the χ 2 test. All p values were obtained two-sided, and p < .05 were considered statistically significant before correction. In order to reduce the error detection rate of multiple tests, after Bonferroni correction, p < .05/(81*11) was indicated statistically significant. The structure (version 2.3.4) software (Excoffier, Laval, & Schneider, 2007) was used to analyze and compare the genetic structure of 12 populations. The value of Fst was calculated using Arlequin (version 3.1) software to infer the degree of genetic differentiation between populations (Evanno, Regnaut, & Goudet, 2005) .
| RESULTS
| VIP variants identification
By searching the VIP variants listed in the PharmGKB database, we selected 81 VIP variants for study. The basic characteristics of the selected variants were listed in Table S1 .
| Analyses of population genetic structures
The genetic differentiation degree of allele frequencies between Bai and other 11 populations was compared using Fst statistics. An Fst value of less than 0.15 indicates that there is no significant genetic difference between the two populations. And pairwise FST values between the Bai population and the other 11 HapMap populations ranged from 0.0157 to 0.2213 (Table 3) . Comparing other populations, the lowest level of differentiation was observed between the Bai and CHB populations (FST = 0.0157), followed by the JPT (FST = 0.0203), whereas the greatest divergence was found in the YRI population (FST = 0.2213). The Bayesian-based structure analysis of the genetic relationship among 12 populations was shown in Figure 1 , most suitable K was observed at K = 6, where the each individual 
T A B L E 1 Basic Characteristics of the selected VIP variants from the PharmGKB database and genotype frequencies in Bai population
SNP ID
was represented by a vertical column partitioned into different color segments. The results revealed that the Bai population was most similar to the CHB and JPT populations, which was consistent with the results in Table 3 .
| DISCUSSION
Today, the rapidly advancing pharmacogenetics is increasingly focused on the interethnic or interracial differences in drug metabolism to identify the genetic backgrounds of these variations. For the first time, our study genotyped the variants related to drug reactions in the Bai ethnic group, and compared the genotype frequencies with the other 11 HapMap populations. Our results suggested that the expression of many VIP variants were significantly different between the Bai population and other populations. Among these variants, rs20417, rs4148323, and rs1131596 were significantly differentially expressed in the Bai population, compared to the 11 populations. We also found that the genetic backgrounds of the Bai and CHB populations were similar, but significantly different from the YRI populations. Rs20417 is a significant variant of the prostaglandin-endoperoxide synthase 2 (PTGS2) gene (Hung et al., 2017) . PTGS2 gene also known as cyclooxygenase 2 (COX-2), located on chromosome 1, is the key enzyme in prostaglandin biosynthesis that can converts arachidonate to prostaglandin H2 (PGH2) (Lucido, Orlando, Vecchio, & Malkowski, 2016) . It has been widely reported that the polymorphism of rs20417 is associated with many diseases, such as myocardial infarction or stroke (Lemaitre et al., 2009 ). Previous pharmacogenomics studies have revealed that PTGS2 was the targets of nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin and ibuprofen Lee et al., 2008 ) also reported that patients with a CC genotype may have an increased risk of coronary artery disease when treated with aspirin compared to patients with a GG or CG genotype. Rozenn et al. (Lemaitre et al., 2009 ) studies have shown that that variation in TBXAS1 and PTGIS may influence Myocardial Infarction (MI) risk and carriers of rs20417 C allele might derive greater benefits from aspirin use in primary prevention in comparison with non-carriers. In our study, the C allele frequency of the Bai nationality was as high as 80%, indicating that the Bai population increased the risk of coronary artery disease when treated with aspirin. At the same time, when using aspirin to prevent MI risk, the Bai population can get more benefits.
Rs4148323 is an intron variant of the UGT1A1 gene on human chromosome 2q37, which encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway (Sugatani et al., 2001) . It plays an important role in catalyzing the formation of bound bilirubin by unbound bilirubin (Liu, Lu, et al., 2017 Bold italics indicates that after adjustment p < .05/(80*11) the locus has statistically significant. (Continued) of thrombocytopenia (Han, Lim, Park, Lee, & Lee, 2009) or diarrhea (Takekuma et al., 2006) when treated with irinotecan-based regimens and may also increase tumor response, progression-free survival Period or overall survival compared with patients with AA or AG genotype. In our study, we found that the G allele frequency of rs 4,148,323 in the Bai population was very high, indicating that the cancer patients in the Bai population can reduce the risk of thrombocytopenia or diarrhea. Other studies have demonstrated that patients with angina or heart failure carrying the G allele are more likely to increase glucuronidation of carvedilol than carriers of the A allele (Boyd et al., 2006) . One study reported that patients with the G allele had a reduced risk of developing hyperbilirubinemia during treatment with indinavir, compared to HIV patients with the A allele (Bohanec Grabar et al., 2012) . These findings pointed that rs4148323 polymorphism may be a useful pharmacogenomics point for providing rational and effectively tailored therapy for the Bai ethnic group. The rs1131596 variant is located in the Solute Carrier Family 19 Member 1 (SLC19A1) gene, which encodes a folate transporter and is involved in the regulation of intracellular folate concentrations (Whetstine, Flatley, & Matherly, 2002) . In our study, we found that the genotype frequency of rs1131596 was significantly different between the Bai and the other 11 races. One study reported that a linkage group (LD) rs1051266/rs11315962, which may influence the SLC19A1 function, such as changing the SLC19A1 splicing (Bohanec Grabar et al., 2012) . Clinical evidence proposed that variants of rs1131596 and rs1051266 have protective effects against the risk of discontinuation of methotrexate toxicity (MTX) treatment due to toxicity and infection (Chatzikyriakidou et al., 2007) . The allele G of rs1131596 can reduce the expression of SLC19A1 compared to allele A, but the allele G was not associated with response to methotrexate in people with arthritis, rheumatoid and in children with progenitor cell lymphoblastic leukemia-lymphoma (Liu, Gao, et al., 2017) . However, the pharmacoge-nomics information of the rs3807375 variant requires more in-depth investigation.
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Our results supplemented the pharmacogenomic information of the Bai population and shed light on the differences in selected genetic polymorphisms between the Bai population and 11 other populations around the world. In addition, these results provided a solid foundation for the Bai population to use drugs more rationally and safely. But our sample of the Bai population was relatively small and the results must be further validated in a larger sample set.
| CONCLUSIONS
We identified the characteristics of 81 VIP variants of Bai population from southwestern China, and found that the genetic background of Bai population in Yunnan was closest to CHD population. This information helps Bai population to develop appropriate personalized treatment strategies, including appropriate drugs and the right dose.
| THE INFLUENCE OF OUR RESULTS IN CLINICAL APPLICATION
Different populations may have different genotypes due to differences in ancestry, geographical location, lifestyle, etc., and different genotypes have certain differences in response to corresponding drugs. Our study found that the genotypes of some VIP sites of Bai population were different from those of 11 global representative groups, so this study is helpful for the individualized treatment of Bai population in clinical practice.
| ETHICS APPROVAL AND CONSENT TO PARTICIPATE
All volunteers were informed the procedures and purpose of the study, both orally and in writing. They also agreed to provide blood samples and signed informed consent forms. The clinical protocol was approved by the Ethics Committee of Yunnan First People's Hospital and was performed in accordance with the Declaration of Helsinki.
| CONSENT FOR PUBLICATION
Not applicable.
